董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael J. Welsh | 男 | Director | 68 | 3.35万美元 | 未持股 | 2017-04-21 |
| Geoffrey Harris | 男 | Director | 55 | 4.10万美元 | 未持股 | 2017-04-21 |
| Howard McLeod | 男 | Director | 51 | 3.10万美元 | 未持股 | 2017-04-21 |
| John Pappajohn | 男 | Chairman of the Board | 88 | 21.60万美元 | 未持股 | 2017-04-21 |
| Franklyn G. Prendergast | 男 | Director | 72 | 3.60万美元 | 未持股 | 2017-04-21 |
| Raju S. K. Chaganti | 男 | Director | 84 | 12.60万美元 | 未持股 | 2017-04-21 |
| Panna L. Sharma | 男 | Director, President and Chief Executive Officer | 46 | 58.65万美元 | 未持股 | 2017-04-21 |
| Edmund Cannon | 男 | Director | 72 | 3.60万美元 | 未持股 | 2017-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rita Shaknovich | 女 | Medical Director, Vice President, Hematopathology Services | 49 | 未披露 | 未持股 | 2017-04-21 |
| John A. Roberts | 男 | Chief Operating Officer | 58 | 30.20万美元 | 未持股 | 2017-04-21 |
| Panna L. Sharma | 男 | Director, President and Chief Executive Officer | 46 | 58.65万美元 | 未持股 | 2017-04-21 |
董事简历
中英对照 | 中文 | 英文- Michael J. Welsh
-
Michael J. Welsh是我们的董事会成员和Howard Hughes Medical Institute（霍华德·休斯医学研究所）的研究员，自1989年以来担任该职位，Howard Hughes Medical Institute内科医学和分子生理学和生物物理学教授，自1987年以来担任该职位。他是the Roy J. Carver Biomedical Research内科医学和分子生理学和生物物理学主席。他也是神经外科教授，the Cystic Fibrosis Research Center的董事和the Pappajohn Biomedical Institute的董事。他于1997年当选到医学研究所（the Institute of Medicine），1998年当选到美国艺术与科学院（the American Academy of Arts and Sciences），2000年当选到国家科学院（the National Academy of Sciences）。他共同创办两家公司，Exemplar Genetics（民营生物技术公司）和Emmyon, Inc.（民营生物技术公司）。他获得the University of Iowa的医学博士学位和内科医学培训，在the University of California at San Francisco和休斯顿the University of Texas训练肺医学和研究。
Michael J. Welsh is a member of our Board and is a Howard Hughes Medical Institute Investigator, a position he has held since 1989. He is a Professor and the Roy J. Carver Biomedical Research Chair in Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa, a position he has held since 1987. He is also Director of the Cystic Fibrosis Research Center and Director of the Pappajohn Biomedical Institute. Dr. Welsh was elected to the Institute of Medicine in 1997 the American Academy of Arts and Sciences in 1998 and the National Academy of Sciences in 2000. Dr. Welsh has co-founded three companies, Exemplar Genetics, which was purchased by Intrexon Corporation NYSE: XON in January 2015 Emmyon, Inc., a privately-held biotechnology company, and Talee Bio, Inc., a privately-held biotechnology company. Dr. Welsh received his MD and internal medicine training at the University of Iowa and trained in pulmonary medicine and research at the University of California at San Francisco and the University of Texas in Houston. - Michael J. Welsh是我们的董事会成员和Howard Hughes Medical Institute（霍华德·休斯医学研究所）的研究员，自1989年以来担任该职位，Howard Hughes Medical Institute内科医学和分子生理学和生物物理学教授，自1987年以来担任该职位。他是the Roy J. Carver Biomedical Research内科医学和分子生理学和生物物理学主席。他也是神经外科教授，the Cystic Fibrosis Research Center的董事和the Pappajohn Biomedical Institute的董事。他于1997年当选到医学研究所（the Institute of Medicine），1998年当选到美国艺术与科学院（the American Academy of Arts and Sciences），2000年当选到国家科学院（the National Academy of Sciences）。他共同创办两家公司，Exemplar Genetics（民营生物技术公司）和Emmyon, Inc.（民营生物技术公司）。他获得the University of Iowa的医学博士学位和内科医学培训，在the University of California at San Francisco和休斯顿the University of Texas训练肺医学和研究。
- Michael J. Welsh is a member of our Board and is a Howard Hughes Medical Institute Investigator, a position he has held since 1989. He is a Professor and the Roy J. Carver Biomedical Research Chair in Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa, a position he has held since 1987. He is also Director of the Cystic Fibrosis Research Center and Director of the Pappajohn Biomedical Institute. Dr. Welsh was elected to the Institute of Medicine in 1997 the American Academy of Arts and Sciences in 1998 and the National Academy of Sciences in 2000. Dr. Welsh has co-founded three companies, Exemplar Genetics, which was purchased by Intrexon Corporation NYSE: XON in January 2015 Emmyon, Inc., a privately-held biotechnology company, and Talee Bio, Inc., a privately-held biotechnology company. Dr. Welsh received his MD and internal medicine training at the University of Iowa and trained in pulmonary medicine and research at the University of California at San Francisco and the University of Texas in Houston.
- Geoffrey Harris
-
Geoffrey Harris是我们的董事会成员，是c7 Advisors（资金管理和医疗咨询公司）的管理合伙人。从2011年到2014年他担任Cantor Fitzgerald医疗保健投资银行业务集团的董事总经理兼联席主管，从2009年到2011年他在Gleacher & Company担任类似的职位。他目前也服务于American Care Source （Nasdaq：ANCI）（医疗保健服务公司），Amperic, Inc.（民营科技公司）和PointRight Inc.（民营软件公司）的董事会。他毕业于麻省理工学院（MIT）斯隆管理学院（Sloan School of Management），获得财务管理硕士学位。
Geoffrey Harris is a member of our Board and is a managing partner of c7 Advisors a money management and healthcare advisory firm. From 2011 to 2014 he served as a managing director and co-head of the healthcare investment banking group at Cantor Fitzgerald, and from 2009-2011 he held a similar position at Gleacher & Company. Mr. Harris is also currently on the board of directors of MYnd Analytics (Nasdaq: CNSO), a data analysis company focused on improving mental health care, connectRN, a private company focused on nurse staffing, and PointRight Inc., a privately-held software company. Mr. Harris graduated from MIT’s Sloan School of Management with an MS in Finance Management. - Geoffrey Harris是我们的董事会成员，是c7 Advisors（资金管理和医疗咨询公司）的管理合伙人。从2011年到2014年他担任Cantor Fitzgerald医疗保健投资银行业务集团的董事总经理兼联席主管，从2009年到2011年他在Gleacher & Company担任类似的职位。他目前也服务于American Care Source （Nasdaq：ANCI）（医疗保健服务公司），Amperic, Inc.（民营科技公司）和PointRight Inc.（民营软件公司）的董事会。他毕业于麻省理工学院（MIT）斯隆管理学院（Sloan School of Management），获得财务管理硕士学位。
- Geoffrey Harris is a member of our Board and is a managing partner of c7 Advisors a money management and healthcare advisory firm. From 2011 to 2014 he served as a managing director and co-head of the healthcare investment banking group at Cantor Fitzgerald, and from 2009-2011 he held a similar position at Gleacher & Company. Mr. Harris is also currently on the board of directors of MYnd Analytics (Nasdaq: CNSO), a data analysis company focused on improving mental health care, connectRN, a private company focused on nurse staffing, and PointRight Inc., a privately-held software company. Mr. Harris graduated from MIT’s Sloan School of Management with an MS in Finance Management.
- Howard McLeod
-
Howard McLeod是我们的董事会成员和是the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center的医疗总监，担任the Moffitt Cancer Center人口科学部（Division of Population Sciences）的高级成员。他在2013年9月加入Moffitt Cancer Center（在自2006年以来担任the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy（北卡罗莱纳大学药物基因组学研究所）的创始董事之后）。他还从2006年到2013年在the UNC Eshelman School of Pharmacy担任Fred Eshelman特聘教授（Fred Eshelman Distinguished Professor）的杰出头衔。他发表了超过475篇同行评议论文（药物基因组学，应用治疗和临床药理学）。他担任的Gentris Corporation首席科学顾问和董事会成员（在2014年7月其被公司收购之前），自2014年7月以来服务于公司的科学咨询委员会（Scientific Advisory Board）。
Howard McLeod is a member of our Board and is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center, and as a Senior Member of the Moffitt Cancer Center’s Division of Population Sciences. He also chairs the Department of Individualized Cancer Management at Moffitt. He joined Moffitt Cancer Center in September 2013 after having served as a Founding Director of the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy since 2006. Dr. McLeod also held the prestigious title of Fred Eshelman Distinguished Professor at the UNC Eshelman School of Pharmacy from 2006 to 2013. Dr. McLeod has published over 500 peer-reviewed papers on pharmacogenomics, applied therapeutics and clinical pharmacology. He had served as Chief Scientific Advisor and a member of the board of directors of Gentris Corporation before its acquisition by the Company in July 2014 and has served since July 2014 on the Company’s Scientific Advisory Board. - Howard McLeod是我们的董事会成员和是the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center的医疗总监，担任the Moffitt Cancer Center人口科学部（Division of Population Sciences）的高级成员。他在2013年9月加入Moffitt Cancer Center（在自2006年以来担任the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy（北卡罗莱纳大学药物基因组学研究所）的创始董事之后）。他还从2006年到2013年在the UNC Eshelman School of Pharmacy担任Fred Eshelman特聘教授（Fred Eshelman Distinguished Professor）的杰出头衔。他发表了超过475篇同行评议论文（药物基因组学，应用治疗和临床药理学）。他担任的Gentris Corporation首席科学顾问和董事会成员（在2014年7月其被公司收购之前），自2014年7月以来服务于公司的科学咨询委员会（Scientific Advisory Board）。
- Howard McLeod is a member of our Board and is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center, and as a Senior Member of the Moffitt Cancer Center’s Division of Population Sciences. He also chairs the Department of Individualized Cancer Management at Moffitt. He joined Moffitt Cancer Center in September 2013 after having served as a Founding Director of the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy since 2006. Dr. McLeod also held the prestigious title of Fred Eshelman Distinguished Professor at the UNC Eshelman School of Pharmacy from 2006 to 2013. Dr. McLeod has published over 500 peer-reviewed papers on pharmacogenomics, applied therapeutics and clinical pharmacology. He had served as Chief Scientific Advisor and a member of the board of directors of Gentris Corporation before its acquisition by the Company in July 2014 and has served since July 2014 on the Company’s Scientific Advisory Board.
- John Pappajohn
-
John Pappajohn自2004年11月以来曾担任美国CareSource控股的董事。他自1969年以来一直是Pappajohn资本资源公司（该公司是一家风险资本公司）的总裁和唯一所有者，和Equity Dynamics金融咨询公司的总裁和唯一所有者，两个公司都坐落在爱荷华州得梅因。他是以下上市公司董事会的董事：癌症遗传学公司，提供癌症的诊断产品和服务市场（2009年11月以来）；和中枢神经系统反应公司，该公司使用EEG-generated生物标志物用于个性化医学精神病学（自2009年8月）。
John Pappajohn was appointed to our board of directors on March 18 2019. Since 1969 Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa. Mr. Pappajohn currently serves as Chairman of the Board of Cancer Genetics, Inc. NASDAQ: CGIX, a molecular diagnostics company. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 public companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies. - John Pappajohn自2004年11月以来曾担任美国CareSource控股的董事。他自1969年以来一直是Pappajohn资本资源公司（该公司是一家风险资本公司）的总裁和唯一所有者，和Equity Dynamics金融咨询公司的总裁和唯一所有者，两个公司都坐落在爱荷华州得梅因。他是以下上市公司董事会的董事：癌症遗传学公司，提供癌症的诊断产品和服务市场（2009年11月以来）；和中枢神经系统反应公司，该公司使用EEG-generated生物标志物用于个性化医学精神病学（自2009年8月）。
- John Pappajohn was appointed to our board of directors on March 18 2019. Since 1969 Mr. Pappajohn has been the President and sole owner of Pappajohn Capital Resources, a venture capital firm, and President and sole owner of Equity Dynamics, Inc., a financial consulting firm, both located in Des Moines, Iowa. Mr. Pappajohn currently serves as Chairman of the Board of Cancer Genetics, Inc. NASDAQ: CGIX, a molecular diagnostics company. Mr. Pappajohn was chosen to serve as a director of our company because of his unparalleled experience serving as a director of more than 40 public companies and the substantial insight he has gained into the life sciences and healthcare industries by actively investing in the industries for more than 40 years, and by founding and supporting several public healthcare companies.
- Franklyn G. Prendergast
-
Franklyn G. Prendergast，他是梅奥医学院：生物化学和分子生物学的爱德蒙和马里昂古根海姆教授（1986- 至今），分子药理学和实验治疗学教授（1987- 至今）；梅奥诊所中心的个性化医学的名誉主任（2006 - 2012）。
Franklyn G. Prendergast,M.D., Ph.D ., has served as a member of Neubase Therapeutics, Inc. Board since July 2019. Dr. Prendergast retired from the Mayo Clinic in 2014 and is currently the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics at Mayo Medical School. At the Mayo Clinic, he served in several capacities, most significantly, as the Director for Research 1989–1992, inclusive, Member of the Mayo Clinic Board of Governors and Executive Committee 1991–2007, and Member of the Mayo Clinic Board of Trustees from 1991-2009, inclusive. From 1994 to 2006, he served as a director of Mayo Clinic Cancer Center. He also previously held several other teaching positions at the Mayo Medical School from 1975 through 2014. Dr. Prendergast has served for the National Institute of Health on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; and the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the National Institute of Health and the National Research Council of the National Academy of Sciences. He is a member of the board of directors of Immunome, Inc. (Nasdaq: IMNM) and its nominating and corporate governance committee, a member of the board of director of Cancer Genetics, Inc. (Nasdaq: CGIX) and its audit, compensation and nominating committees, a member of the board of directors of Lantern Pharma, Inc. (Nasdaq: LTRN) and its audit and nominating committees, and a member of the board of directors of the Infectious Disease Research Institute (IDRI). He previously served on the board of directors of Eli Lilly & Co. from 1995 to 2017 and was a member of Eli Lilly''s science and technology committee and public policy and compliance committee, and he previously served on the board of directors of Medibio Limited (ASX: MEB) (OTCQB: MDBIF). Dr. Prendergast obtained his medical degree with honors from the University of West 98 Table of Contents Indies and attended Oxford University as a Rhodes Scholar, earning an M.A. degree in physiology. He obtained his Ph.D. in Biochemistry at the University of Minnesota. - Franklyn G. Prendergast，他是梅奥医学院：生物化学和分子生物学的爱德蒙和马里昂古根海姆教授（1986- 至今），分子药理学和实验治疗学教授（1987- 至今）；梅奥诊所中心的个性化医学的名誉主任（2006 - 2012）。
- Franklyn G. Prendergast,M.D., Ph.D ., has served as a member of Neubase Therapeutics, Inc. Board since July 2019. Dr. Prendergast retired from the Mayo Clinic in 2014 and is currently the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics at Mayo Medical School. At the Mayo Clinic, he served in several capacities, most significantly, as the Director for Research 1989–1992, inclusive, Member of the Mayo Clinic Board of Governors and Executive Committee 1991–2007, and Member of the Mayo Clinic Board of Trustees from 1991-2009, inclusive. From 1994 to 2006, he served as a director of Mayo Clinic Cancer Center. He also previously held several other teaching positions at the Mayo Medical School from 1975 through 2014. Dr. Prendergast has served for the National Institute of Health on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; and the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the National Institute of Health and the National Research Council of the National Academy of Sciences. He is a member of the board of directors of Immunome, Inc. (Nasdaq: IMNM) and its nominating and corporate governance committee, a member of the board of director of Cancer Genetics, Inc. (Nasdaq: CGIX) and its audit, compensation and nominating committees, a member of the board of directors of Lantern Pharma, Inc. (Nasdaq: LTRN) and its audit and nominating committees, and a member of the board of directors of the Infectious Disease Research Institute (IDRI). He previously served on the board of directors of Eli Lilly & Co. from 1995 to 2017 and was a member of Eli Lilly''s science and technology committee and public policy and compliance committee, and he previously served on the board of directors of Medibio Limited (ASX: MEB) (OTCQB: MDBIF). Dr. Prendergast obtained his medical degree with honors from the University of West 98 Table of Contents Indies and attended Oxford University as a Rhodes Scholar, earning an M.A. degree in physiology. He obtained his Ph.D. in Biochemistry at the University of Minnesota.
- Raju S. K. Chaganti
-
Raju S. K. Chaganti是Cancer Genetics，Inc.的创始人，自公司成立以来一直担任Cancer Genetics, Inc.的董事会成员。Chaganti博士是国际公认的癌症细胞遗传学和分子遗传学的领导者。他是美国专利局颁发的10项专利的发明人，其中3项来自纪念斯隆-凯特琳癌症中心KCC，7项来自癌症遗传学公司，这些专利都与癌症基因发现和癌症基因分析有关。Chaganti博士目前是纪念斯隆-凯特琳癌症中心William E. Snee主席，他是该中心医学和细胞生物学项目的教员。他是Gernster Sloan-Kettering生物医学研究生院和纽约Weill-Cornell药物科学研究生院的教授。他是纪念斯隆-凯特琳癌症中心细胞遗传学服务的负责人，他于1976年建立了该中心，作为该国最早的基于基因的癌症诊断服务之一。Chaganti博士在哈佛大学艺术与科学研究生院获得生物学遗传学博士学位，并在英国医学研究委员会完成博士后培训。此外，他在斯德哥尔摩卡罗林斯卡学院肿瘤生物学系完成了一次休假，重点是实验小鼠肿瘤发生和免疫学。他在遗传学方面发表了大量文章，有超过380个条目的参考书目，包括同行评审的研究文章、书籍章节和书籍。Chaganti博士是获得医学遗传学认证的美国医学遗传学委员会，具有临床细胞遗传学的亚专业。他也是美国医学遗传学学院的创始研究员。
Raju S. K. Chaganti is Cancer Genetics, Inc. founder and has served on Cancer Genetics, Inc. Board since the Company's inception. Dr. Chaganti is an internationally recognized leader in cancer cytogenetics and molecular genetics. He is an inventor on 10 patents issued by the US patent office, 3 from Memorial Sloan-Kettering Cancer Center KCC and 7 from Cancer Genetics, Inc, all related to cancer gene discovery and cancer genetic analysis. Dr. Chaganti currently is the incumbent of the William E. Snee Chair at the Memorial Sloan-Kettering Cancer Center, where he is on the faculty of the Department of Medicine and Cell Biology Program. He is a Professor at the Gernster Sloan- Kettering Graduate School of Biomedical Sciences and at Weill-Cornell Graduate School of Medicinal Sciences, New York, New York. He was the chief of Memorial Sloan-Kettering Cancer Center's cytogenetics service, which he established in 1976 as one of the earliest genetically based cancer diagnostic services in the country. Dr. Chaganti received a Ph.D. in biology genetics from Harvard University Graduate School of Arts and Sciences and completed his post-doctoral training at the Medical Research Council of Great Britain. Additionally, he completed a sabbatical in the Department of Tumor Biology at Karolinska Institute Stockholm, focusing on experimental murine tumorigenesis and immunology. He has published extensively in genetics with a bibliography of over 380 entries comprising peer reviewed research articles, book chapters, and books. Dr. Chaganti is American Board of Medical Genetics certified in medical genetics, with a subspecialty in clinical cytogenetics. He is also a Founding Fellow of the American College of Medical Genetics. - Raju S. K. Chaganti是Cancer Genetics，Inc.的创始人，自公司成立以来一直担任Cancer Genetics, Inc.的董事会成员。Chaganti博士是国际公认的癌症细胞遗传学和分子遗传学的领导者。他是美国专利局颁发的10项专利的发明人，其中3项来自纪念斯隆-凯特琳癌症中心KCC，7项来自癌症遗传学公司，这些专利都与癌症基因发现和癌症基因分析有关。Chaganti博士目前是纪念斯隆-凯特琳癌症中心William E. Snee主席，他是该中心医学和细胞生物学项目的教员。他是Gernster Sloan-Kettering生物医学研究生院和纽约Weill-Cornell药物科学研究生院的教授。他是纪念斯隆-凯特琳癌症中心细胞遗传学服务的负责人，他于1976年建立了该中心，作为该国最早的基于基因的癌症诊断服务之一。Chaganti博士在哈佛大学艺术与科学研究生院获得生物学遗传学博士学位，并在英国医学研究委员会完成博士后培训。此外，他在斯德哥尔摩卡罗林斯卡学院肿瘤生物学系完成了一次休假，重点是实验小鼠肿瘤发生和免疫学。他在遗传学方面发表了大量文章，有超过380个条目的参考书目，包括同行评审的研究文章、书籍章节和书籍。Chaganti博士是获得医学遗传学认证的美国医学遗传学委员会，具有临床细胞遗传学的亚专业。他也是美国医学遗传学学院的创始研究员。
- Raju S. K. Chaganti is Cancer Genetics, Inc. founder and has served on Cancer Genetics, Inc. Board since the Company's inception. Dr. Chaganti is an internationally recognized leader in cancer cytogenetics and molecular genetics. He is an inventor on 10 patents issued by the US patent office, 3 from Memorial Sloan-Kettering Cancer Center KCC and 7 from Cancer Genetics, Inc, all related to cancer gene discovery and cancer genetic analysis. Dr. Chaganti currently is the incumbent of the William E. Snee Chair at the Memorial Sloan-Kettering Cancer Center, where he is on the faculty of the Department of Medicine and Cell Biology Program. He is a Professor at the Gernster Sloan- Kettering Graduate School of Biomedical Sciences and at Weill-Cornell Graduate School of Medicinal Sciences, New York, New York. He was the chief of Memorial Sloan-Kettering Cancer Center's cytogenetics service, which he established in 1976 as one of the earliest genetically based cancer diagnostic services in the country. Dr. Chaganti received a Ph.D. in biology genetics from Harvard University Graduate School of Arts and Sciences and completed his post-doctoral training at the Medical Research Council of Great Britain. Additionally, he completed a sabbatical in the Department of Tumor Biology at Karolinska Institute Stockholm, focusing on experimental murine tumorigenesis and immunology. He has published extensively in genetics with a bibliography of over 380 entries comprising peer reviewed research articles, book chapters, and books. Dr. Chaganti is American Board of Medical Genetics certified in medical genetics, with a subspecialty in clinical cytogenetics. He is also a Founding Fellow of the American College of Medical Genetics.
- Panna L. Sharma
-
Panna L. Sharma，2010年5月成为我们董事会成员，我们的总裁兼潘首席执行官。2001年到2010年，Sharma先生是TSG，一家生命科学专业咨询和顾问公司的创始人和合伙人。在TSG，他领导开发战略措施，企业发展战略以及上市和私营企业的转变。他还领导过70多次生命科学、医疗保健和生物制药公司超过70次的收购和卖方交易。在TSG，他建立了全球诊断指数，全球生物工具指数其它几个生命科学投资市场指数，这些仍被用在生命科学行业。TSG成立之前， Sharma先生是iXL，一家上市电子商务咨询公司的首席战略官，Inc 。 & # 8220；iXL& # 8221；，在那里他领导公司的战略发展和收购活动，是管理团队的成员，帮助公司在1999年6月公司上市。在iXL，他也管理专业电子商务战略实践组，使它的收入从1998年的400万美元增加到2000年超过7500万美元。1996年到1998年，Sharma先生是Interactive Solutions，一家位于马萨诸塞州剑桥专注于医疗和金融服务行业的市场战略咨询公司的合伙人，公司是后来卖给了Omnicom，全球最大的市场分析和营销公司之一。在那之前，Sharma 先生担任Putnam投资管理和美国银行公司的顾问。2001年到2003年，Sharma先生担任EpicEdge，一家医疗保健和注重IT服务管理公司的董事会成员，2008年到2010年，他也担任EndoChoice，一家胃肠疾病治疗市场全球领先公司的董事长。
Panna L. Sharma became a member of our Board and our President and Chief Executive Officer in May of 2010. Additionally, he serves as the general manager of Oncospire Genomics. Mr. Sharma was at TSG Partners, a specialty life sciences consultancy and advisory company, from 2001 to 2010 where he was the Managing Partner and founder. At TSG he led the development of strategic initiatives, corporate growth strategy and corporate turnarounds for both public and private companies. He also led over 70 buy and sell-side transactions for life sciences, healthcare and biopharma companies. At TSG, he established the Global Diagnostics Index, the Global Biotools Index and several other life science capital markets indices that are still used in the life science industry. Prior to founding TSG, Mr. Sharma was the Chief Strategy Officer for iXL Enterprises, Inc. “iXL”, a public e-business consultancy where he led strategy development and acquisitions activity and was part of the management team that aided in taking the company public in June 1999. At iXL, he also managed the specialty e-business strategy practices group that grew from under $4 million in revenue in 1998 to over $75 million in 2000. From 1996 to 1998 Mr. Sharma was a partner at Interactive Solutions, Inc., a marketing and strategy consultancy focused on health care and financial services in Cambridge, Massachusetts, that was sold to Omnicom, Inc., one of the largest global market analysis and marketing companies. Prior to that time, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma has also served on the board of directors of EpicEdge, a health care and government focused IT services firm, from 2001 to 2003 and as chairman of the Advisory Board for EndoChoice, a global leader for the gastrointestinal treatment market from 2008 to 2010. - Panna L. Sharma，2010年5月成为我们董事会成员，我们的总裁兼潘首席执行官。2001年到2010年，Sharma先生是TSG，一家生命科学专业咨询和顾问公司的创始人和合伙人。在TSG，他领导开发战略措施，企业发展战略以及上市和私营企业的转变。他还领导过70多次生命科学、医疗保健和生物制药公司超过70次的收购和卖方交易。在TSG，他建立了全球诊断指数，全球生物工具指数其它几个生命科学投资市场指数，这些仍被用在生命科学行业。TSG成立之前， Sharma先生是iXL，一家上市电子商务咨询公司的首席战略官，Inc 。 & # 8220；iXL& # 8221；，在那里他领导公司的战略发展和收购活动，是管理团队的成员，帮助公司在1999年6月公司上市。在iXL，他也管理专业电子商务战略实践组，使它的收入从1998年的400万美元增加到2000年超过7500万美元。1996年到1998年，Sharma先生是Interactive Solutions，一家位于马萨诸塞州剑桥专注于医疗和金融服务行业的市场战略咨询公司的合伙人，公司是后来卖给了Omnicom，全球最大的市场分析和营销公司之一。在那之前，Sharma 先生担任Putnam投资管理和美国银行公司的顾问。2001年到2003年，Sharma先生担任EpicEdge，一家医疗保健和注重IT服务管理公司的董事会成员，2008年到2010年，他也担任EndoChoice，一家胃肠疾病治疗市场全球领先公司的董事长。
- Panna L. Sharma became a member of our Board and our President and Chief Executive Officer in May of 2010. Additionally, he serves as the general manager of Oncospire Genomics. Mr. Sharma was at TSG Partners, a specialty life sciences consultancy and advisory company, from 2001 to 2010 where he was the Managing Partner and founder. At TSG he led the development of strategic initiatives, corporate growth strategy and corporate turnarounds for both public and private companies. He also led over 70 buy and sell-side transactions for life sciences, healthcare and biopharma companies. At TSG, he established the Global Diagnostics Index, the Global Biotools Index and several other life science capital markets indices that are still used in the life science industry. Prior to founding TSG, Mr. Sharma was the Chief Strategy Officer for iXL Enterprises, Inc. “iXL”, a public e-business consultancy where he led strategy development and acquisitions activity and was part of the management team that aided in taking the company public in June 1999. At iXL, he also managed the specialty e-business strategy practices group that grew from under $4 million in revenue in 1998 to over $75 million in 2000. From 1996 to 1998 Mr. Sharma was a partner at Interactive Solutions, Inc., a marketing and strategy consultancy focused on health care and financial services in Cambridge, Massachusetts, that was sold to Omnicom, Inc., one of the largest global market analysis and marketing companies. Prior to that time, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma has also served on the board of directors of EpicEdge, a health care and government focused IT services firm, from 2001 to 2003 and as chairman of the Advisory Board for EndoChoice, a global leader for the gastrointestinal treatment market from 2008 to 2010.
- Edmund Cannon
-
Edmund Cannon，是我们董事会成员，是Cape Cod临床研究中心的创始人兼总裁，中心是专门寻找委员会审查批准的机构，同意了诊断和制药行业的试验，设立研究支持FDA制药和生物技术公司的意见书。以前，Cannon先生是Franey医学实验室的市场营销和业务顾问。Cannon先生也负责Pharmacia Diagnostics大部分国家的销售，是Alletess的副总裁和创始人之一。 Canon先生波士顿州立大学学位和普罗维登斯学院的硕士学位。
Edmund Cannon is a member of our Board and is founder and President of the Clinical Research Center of Cape Cod, which specializes in finding institutional review board approved, consented specimens for the diagnostics and pharmaceutical industries, and in setting up studies to support FDA submissions for pharmaceutical and biotechnology companies. Previously, Mr. Cannon was a marketing and operations consultant for Franey Medical Labs. Mr. Cannon also formerly had the most national sales for Pharmacia Diagnostics Inc., and was a vice president and co-founder of Alletess, Inc. Mr. Canon has a degree from Boston State College and attended a Master’s program at Providence College. - Edmund Cannon，是我们董事会成员，是Cape Cod临床研究中心的创始人兼总裁，中心是专门寻找委员会审查批准的机构，同意了诊断和制药行业的试验，设立研究支持FDA制药和生物技术公司的意见书。以前，Cannon先生是Franey医学实验室的市场营销和业务顾问。Cannon先生也负责Pharmacia Diagnostics大部分国家的销售，是Alletess的副总裁和创始人之一。 Canon先生波士顿州立大学学位和普罗维登斯学院的硕士学位。
- Edmund Cannon is a member of our Board and is founder and President of the Clinical Research Center of Cape Cod, which specializes in finding institutional review board approved, consented specimens for the diagnostics and pharmaceutical industries, and in setting up studies to support FDA submissions for pharmaceutical and biotechnology companies. Previously, Mr. Cannon was a marketing and operations consultant for Franey Medical Labs. Mr. Cannon also formerly had the most national sales for Pharmacia Diagnostics Inc., and was a vice president and co-founder of Alletess, Inc. Mr. Canon has a degree from Boston State College and attended a Master’s program at Providence College.
高管简历
中英对照 | 中文 | 英文- Rita Shaknovich
Rita Shaknovich，2015年7月1日她被任命为我们医学董事和血液病理学副总裁。她是医师科学家。加入公司之前从2008年4月到2015年6月，她曾是Weill Cornell Medical College的副教授。她在Weill Cornell Medical College的实验室研究在正常B细胞发育和表观遗传改变导致肿瘤转变时基因调节的表观机制。她的研究是由NIH、STARR Cancer Consortium、Leukemia and Lymphoma Foundation和Lymphoma Research Foundation创立。她的实验室将全基因组方法应用到概要基因组、在不同的发展阶段和不同亚型的B细胞的转录组和甲基化组淋巴瘤以识别异常的肿瘤的表观遗传机制的转换。Weill Cornell Medical College之前从2004年8月到2008年4月，她曾是Albert Einstein College of Medicine的副教授。她获得纽约Mount Sinai School of Medicine的the Medical Scientist training program硕士和博士学。此前，她完成血液病理学方向临床解剖病理学的培训以及Weill Cornell Medical College的the laboratory of Dr. Ari Melnick的研究生训练。她的博士和博士后工作培训集中在血液恶性肿瘤的病理学。
Rita Shaknovich, On July 1 2015 Dr. Rita Shaknovich was appointed as our Medical Director and Vice President of Hematopathology Services. Dr. Shaknovich changed her status with us effective March 27 2017 from a full time employee to a part-time, independent consultant, so that she could return to academic research. As a part-time consultant, she continues to serve as our Group Medical Director, an executive officer position, and as the co-chair of our Clinical Advisory Board. Dr. Shaknovich is a physician scientist and prior to joining the Company she was an Assistant Professor at Weill Cornell Medical College from April 2008 to June 2015. Her laboratory in Weill Cornell Medical College studied epigenetic mechanisms of gene regulation during normal B cell development and epigenetic changes that contribute to neoplastic transformation. Her research was funded by such agencies as NIH, STARR Cancer Consortium, Leukemia and Lymphoma Foundation and Lymphoma Research Foundation. Her lab used genome-wide approaches to profile genome, transcriptome and methylome of B cells at different stages of development and of different subtypes of Lymphomas in order to identify novel epigenetic mechanisms of neoplastic transformation. Prior to Weill Cornell Medical College, from August 2004 to April 2008 she was an Assistant Professor at Albert Einstein College of Medicine. She received her MD and PhD degrees from the Medical Scientist training program in Mount Sinai School of Medicine in New York, after which she completed clinical training in Anatomic Pathology specializing in Hematopathology and finished her post-doctoral training in the laboratory of Dr. Ari Melnick in Weill Cornell Medical College. Dr. Shaknovich’s PhD work and her postdoctoral training focused on pathobiology of hematologic malignancies.- Rita Shaknovich，2015年7月1日她被任命为我们医学董事和血液病理学副总裁。她是医师科学家。加入公司之前从2008年4月到2015年6月，她曾是Weill Cornell Medical College的副教授。她在Weill Cornell Medical College的实验室研究在正常B细胞发育和表观遗传改变导致肿瘤转变时基因调节的表观机制。她的研究是由NIH、STARR Cancer Consortium、Leukemia and Lymphoma Foundation和Lymphoma Research Foundation创立。她的实验室将全基因组方法应用到概要基因组、在不同的发展阶段和不同亚型的B细胞的转录组和甲基化组淋巴瘤以识别异常的肿瘤的表观遗传机制的转换。Weill Cornell Medical College之前从2004年8月到2008年4月，她曾是Albert Einstein College of Medicine的副教授。她获得纽约Mount Sinai School of Medicine的the Medical Scientist training program硕士和博士学。此前，她完成血液病理学方向临床解剖病理学的培训以及Weill Cornell Medical College的the laboratory of Dr. Ari Melnick的研究生训练。她的博士和博士后工作培训集中在血液恶性肿瘤的病理学。
- Rita Shaknovich, On July 1 2015 Dr. Rita Shaknovich was appointed as our Medical Director and Vice President of Hematopathology Services. Dr. Shaknovich changed her status with us effective March 27 2017 from a full time employee to a part-time, independent consultant, so that she could return to academic research. As a part-time consultant, she continues to serve as our Group Medical Director, an executive officer position, and as the co-chair of our Clinical Advisory Board. Dr. Shaknovich is a physician scientist and prior to joining the Company she was an Assistant Professor at Weill Cornell Medical College from April 2008 to June 2015. Her laboratory in Weill Cornell Medical College studied epigenetic mechanisms of gene regulation during normal B cell development and epigenetic changes that contribute to neoplastic transformation. Her research was funded by such agencies as NIH, STARR Cancer Consortium, Leukemia and Lymphoma Foundation and Lymphoma Research Foundation. Her lab used genome-wide approaches to profile genome, transcriptome and methylome of B cells at different stages of development and of different subtypes of Lymphomas in order to identify novel epigenetic mechanisms of neoplastic transformation. Prior to Weill Cornell Medical College, from August 2004 to April 2008 she was an Assistant Professor at Albert Einstein College of Medicine. She received her MD and PhD degrees from the Medical Scientist training program in Mount Sinai School of Medicine in New York, after which she completed clinical training in Anatomic Pathology specializing in Hematopathology and finished her post-doctoral training in the laboratory of Dr. Ari Melnick in Weill Cornell Medical College. Dr. Shaknovich’s PhD work and her postdoctoral training focused on pathobiology of hematologic malignancies.
- John A. Roberts
John A. Roberts，他在2016年7月11日被任命为我们首席运营官。加入我们之前的从2015年8月1日到2016年6月30日，他担任VirMedica, Inc.（一个创新技术解决方案公司，提供了一个端到端的平台，优化专业药品制造商和药房的产品商业化和管理）的首席财务官。VirMedica之前的从2011年8月1日到2015年7月31日，他担任AdvantEdge Healthcare Solutions（全球医疗保健分析和服务组织）的财务和行政总监。此前，他曾是InfoLogix, Inc.（一家上市医疗中心移动软件和解决方案提供商）的首席财务官和财务主管。他也担任领先的公共医疗器械和医疗服务公司的首席财务官职务，包括Clarient, Inc.（上市诊断实验室服务的供应商）和Daou Systems, Inc.（上市医疗IT软件开发和服务公司）。此外，他担任MEDecision, Inc.、HealthOnline, Inc.和the Center for Health Information的重要高级执行职务。他持有 the University of Maine的理学学士和工商管理硕士学位。他是印度班加罗尔AdvantEdge Healthcare Solutions Private Limited的董事长。他也是the Drug Information Association的董事会成员和财务委员会主席。
John A. Roberts, On July 11 2016 Mr. Roberts was appointed as our Chief Operating Officer. Prior to joining us, from August 1 2015 to June 30 2016 Mr. Roberts served as the Chief Financial Officer for VirMedica, Inc., an innovative technology solutions company that provides an end-to-end platform that enables specialty drug manufacturers and pharmacies to optimize product commercialization and management. Prior to VirMedica, from August 1 2011 to July 31 2015 Mr. Roberts was the Chief Financial and Administrative Officer for AdvantEdge Healthcare Solutions, a global healthcare analytics and services organization. Prior to that, Mr. Roberts was the Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded healthcare-centric mobile software and solutions provider. He has also held CFO roles at leading public medical device and healthcare services firms including Clarient, Inc., a publicly-traded provider of diagnostic laboratory services and Daou Systems, Inc., a publicly-traded healthcare IT software development and services firm. In addition, he has held key senior executive roles with MEDecision, Inc., HealthOnline, Inc. and the Center for Health Information. Mr. Roberts earned a Bachelor of Science and a Master’s degree in Business Administration from the University of Maine. He is a member of the Board of Directors and Chairman Elect for the Drug Information Association, a global neutral forum enabling drug developers and regulators access to education and collaboration.- John A. Roberts，他在2016年7月11日被任命为我们首席运营官。加入我们之前的从2015年8月1日到2016年6月30日，他担任VirMedica, Inc.（一个创新技术解决方案公司，提供了一个端到端的平台，优化专业药品制造商和药房的产品商业化和管理）的首席财务官。VirMedica之前的从2011年8月1日到2015年7月31日，他担任AdvantEdge Healthcare Solutions（全球医疗保健分析和服务组织）的财务和行政总监。此前，他曾是InfoLogix, Inc.（一家上市医疗中心移动软件和解决方案提供商）的首席财务官和财务主管。他也担任领先的公共医疗器械和医疗服务公司的首席财务官职务，包括Clarient, Inc.（上市诊断实验室服务的供应商）和Daou Systems, Inc.（上市医疗IT软件开发和服务公司）。此外，他担任MEDecision, Inc.、HealthOnline, Inc.和the Center for Health Information的重要高级执行职务。他持有 the University of Maine的理学学士和工商管理硕士学位。他是印度班加罗尔AdvantEdge Healthcare Solutions Private Limited的董事长。他也是the Drug Information Association的董事会成员和财务委员会主席。
- John A. Roberts, On July 11 2016 Mr. Roberts was appointed as our Chief Operating Officer. Prior to joining us, from August 1 2015 to June 30 2016 Mr. Roberts served as the Chief Financial Officer for VirMedica, Inc., an innovative technology solutions company that provides an end-to-end platform that enables specialty drug manufacturers and pharmacies to optimize product commercialization and management. Prior to VirMedica, from August 1 2011 to July 31 2015 Mr. Roberts was the Chief Financial and Administrative Officer for AdvantEdge Healthcare Solutions, a global healthcare analytics and services organization. Prior to that, Mr. Roberts was the Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded healthcare-centric mobile software and solutions provider. He has also held CFO roles at leading public medical device and healthcare services firms including Clarient, Inc., a publicly-traded provider of diagnostic laboratory services and Daou Systems, Inc., a publicly-traded healthcare IT software development and services firm. In addition, he has held key senior executive roles with MEDecision, Inc., HealthOnline, Inc. and the Center for Health Information. Mr. Roberts earned a Bachelor of Science and a Master’s degree in Business Administration from the University of Maine. He is a member of the Board of Directors and Chairman Elect for the Drug Information Association, a global neutral forum enabling drug developers and regulators access to education and collaboration.
- Panna L. Sharma
Panna L. Sharma，2010年5月成为我们董事会成员，我们的总裁兼潘首席执行官。2001年到2010年，Sharma先生是TSG，一家生命科学专业咨询和顾问公司的创始人和合伙人。在TSG，他领导开发战略措施，企业发展战略以及上市和私营企业的转变。他还领导过70多次生命科学、医疗保健和生物制药公司超过70次的收购和卖方交易。在TSG，他建立了全球诊断指数，全球生物工具指数其它几个生命科学投资市场指数，这些仍被用在生命科学行业。TSG成立之前， Sharma先生是iXL，一家上市电子商务咨询公司的首席战略官，Inc 。 & # 8220；iXL& # 8221；，在那里他领导公司的战略发展和收购活动，是管理团队的成员，帮助公司在1999年6月公司上市。在iXL，他也管理专业电子商务战略实践组，使它的收入从1998年的400万美元增加到2000年超过7500万美元。1996年到1998年，Sharma先生是Interactive Solutions，一家位于马萨诸塞州剑桥专注于医疗和金融服务行业的市场战略咨询公司的合伙人，公司是后来卖给了Omnicom，全球最大的市场分析和营销公司之一。在那之前，Sharma 先生担任Putnam投资管理和美国银行公司的顾问。2001年到2003年，Sharma先生担任EpicEdge，一家医疗保健和注重IT服务管理公司的董事会成员，2008年到2010年，他也担任EndoChoice，一家胃肠疾病治疗市场全球领先公司的董事长。
Panna L. Sharma became a member of our Board and our President and Chief Executive Officer in May of 2010. Additionally, he serves as the general manager of Oncospire Genomics. Mr. Sharma was at TSG Partners, a specialty life sciences consultancy and advisory company, from 2001 to 2010 where he was the Managing Partner and founder. At TSG he led the development of strategic initiatives, corporate growth strategy and corporate turnarounds for both public and private companies. He also led over 70 buy and sell-side transactions for life sciences, healthcare and biopharma companies. At TSG, he established the Global Diagnostics Index, the Global Biotools Index and several other life science capital markets indices that are still used in the life science industry. Prior to founding TSG, Mr. Sharma was the Chief Strategy Officer for iXL Enterprises, Inc. “iXL”, a public e-business consultancy where he led strategy development and acquisitions activity and was part of the management team that aided in taking the company public in June 1999. At iXL, he also managed the specialty e-business strategy practices group that grew from under $4 million in revenue in 1998 to over $75 million in 2000. From 1996 to 1998 Mr. Sharma was a partner at Interactive Solutions, Inc., a marketing and strategy consultancy focused on health care and financial services in Cambridge, Massachusetts, that was sold to Omnicom, Inc., one of the largest global market analysis and marketing companies. Prior to that time, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma has also served on the board of directors of EpicEdge, a health care and government focused IT services firm, from 2001 to 2003 and as chairman of the Advisory Board for EndoChoice, a global leader for the gastrointestinal treatment market from 2008 to 2010.- Panna L. Sharma，2010年5月成为我们董事会成员，我们的总裁兼潘首席执行官。2001年到2010年，Sharma先生是TSG，一家生命科学专业咨询和顾问公司的创始人和合伙人。在TSG，他领导开发战略措施，企业发展战略以及上市和私营企业的转变。他还领导过70多次生命科学、医疗保健和生物制药公司超过70次的收购和卖方交易。在TSG，他建立了全球诊断指数，全球生物工具指数其它几个生命科学投资市场指数，这些仍被用在生命科学行业。TSG成立之前， Sharma先生是iXL，一家上市电子商务咨询公司的首席战略官，Inc 。 & # 8220；iXL& # 8221；，在那里他领导公司的战略发展和收购活动，是管理团队的成员，帮助公司在1999年6月公司上市。在iXL，他也管理专业电子商务战略实践组，使它的收入从1998年的400万美元增加到2000年超过7500万美元。1996年到1998年，Sharma先生是Interactive Solutions，一家位于马萨诸塞州剑桥专注于医疗和金融服务行业的市场战略咨询公司的合伙人，公司是后来卖给了Omnicom，全球最大的市场分析和营销公司之一。在那之前，Sharma 先生担任Putnam投资管理和美国银行公司的顾问。2001年到2003年，Sharma先生担任EpicEdge，一家医疗保健和注重IT服务管理公司的董事会成员，2008年到2010年，他也担任EndoChoice，一家胃肠疾病治疗市场全球领先公司的董事长。
- Panna L. Sharma became a member of our Board and our President and Chief Executive Officer in May of 2010. Additionally, he serves as the general manager of Oncospire Genomics. Mr. Sharma was at TSG Partners, a specialty life sciences consultancy and advisory company, from 2001 to 2010 where he was the Managing Partner and founder. At TSG he led the development of strategic initiatives, corporate growth strategy and corporate turnarounds for both public and private companies. He also led over 70 buy and sell-side transactions for life sciences, healthcare and biopharma companies. At TSG, he established the Global Diagnostics Index, the Global Biotools Index and several other life science capital markets indices that are still used in the life science industry. Prior to founding TSG, Mr. Sharma was the Chief Strategy Officer for iXL Enterprises, Inc. “iXL”, a public e-business consultancy where he led strategy development and acquisitions activity and was part of the management team that aided in taking the company public in June 1999. At iXL, he also managed the specialty e-business strategy practices group that grew from under $4 million in revenue in 1998 to over $75 million in 2000. From 1996 to 1998 Mr. Sharma was a partner at Interactive Solutions, Inc., a marketing and strategy consultancy focused on health care and financial services in Cambridge, Massachusetts, that was sold to Omnicom, Inc., one of the largest global market analysis and marketing companies. Prior to that time, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma has also served on the board of directors of EpicEdge, a health care and government focused IT services firm, from 2001 to 2003 and as chairman of the Advisory Board for EndoChoice, a global leader for the gastrointestinal treatment market from 2008 to 2010.